AbbVie (NYSE:ABBV) Trading Up 2.6% – Time to Buy?

Posted by Lindsey Winhoffer on Apr 8th, 2026

AbbVie Inc. (NYSE:ABBV – Get Free Report) traded up 2.6% on Wednesday . The company traded as high as $212.22 and last traded at $211.7430. 4,584,249 shares changed hands during trading, a decline of 37% from the average session volume of 7,262,205 shares. The stock had previously closed at $206.37.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie filed suit against the U.S. government seeking clearer guidance on which patients qualify for a federal drug-discount program — a move investors view as an attempt to reduce future compliance risk and uncertain discount liabilities that could protect margins. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
Positive Sentiment: New dermatology data for Skyrizi and Rinvoq presented at the AAD (including Skyrizi label updates) strengthen AbbVie’s growth narrative outside immunology and support longer-term revenue upside from these higher-margin products. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
Positive Sentiment: Recent analyst notes highlight upside: JPMorgan reiterated a constructive view with a $260 target and other bullish pieces emphasize dividends and portfolio renewal — these support investor confidence and income-focused demand. AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns
Neutral Sentiment: Cantor Fitzgerald trimmed its price target from $250 to $240 but kept an overweight rating — slightly reduces upside expectations but maintains buy stance. Cantor Fitzgerald price target note (Benzinga)
Neutral Sentiment: Allergan Aesthetics (an AbbVie unit) announced marketing/community initiatives (The Confidence Collective) and opened a new Allergan Medical Institute center — positive for brand/market share in aesthetics but not material to near-term earnings. BOTOX® Cosmetic Empowers Women Entrepreneurs
Negative Sentiment: AbbVie listed Humira on the TrumpRx platform with a very steep discount (reported ~86%), a pricing move that could pressure Humira revenue and raise questions about pricing strategy and long-term valuation given Humira’s historical contribution to cash flow. AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Morgan Stanley raised their target price on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Evercore decreased their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research note on Tuesday, January 20th. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a research note on Thursday, March 12th. Finally, Piper Sandler raised their target price on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $252.65.

View Our Latest Stock Report on ABBV

AbbVie Stock Up 2.6%

The stock’s fifty day moving average price is $220.95 and its 200 day moving average price is $224.28. The stock has a market cap of $374.40 billion, a PE ratio of 89.72, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the company posted $2.16 earnings per share. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie’s dividend payout ratio is presently 293.22%.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.25% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Norges Bank purchased a new stake in AbbVie in the fourth quarter worth approximately $5,865,055,000. Wellington Management Group LLP boosted its holdings in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Capital World Investors boosted its holdings in AbbVie by 106.3% in the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after purchasing an additional 6,736,161 shares during the last quarter. Cardano Risk Management B.V. boosted its holdings in AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock worth $1,244,112,000 after purchasing an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.